Overview of ideal antilipidemic drugs: Past, present and the future

Clement Atlee  W

doi:10.30574/gscbps.2020.11.3.0162

Authors

Clement Atlee W Assistant Professor, Department of pharmacology, C L Baid Metha College of pharmacy, Thoraipakkam, Chennai-97, Tamilnadu, India.

DOI:

https://doi.org/10.30574/gscbps.2020.11.3.0162

Keywords:

Statins, Atherosclerosis, LDL, Novel drugs to treat hyperlipidemia

Abstract

Atherosclerosis, a disease which affects large and medium sized arteries, is now a leading cause of death in many developed countries. High serum LDL (low density lipoproteins) and VLDL (very low density lipoproteins) levels are considered as atherogenic, whereas high HDL (High Density Lipoproteins) over 60 mg/Dl has a protective effect.Literature reviews were conducted by me from different articles on hypolipidemic drugs and the present review looking forward ideal hypolipidemic drugs with their target of action in the treatment of atherosclerosis.Statins are the first line antilipidemic drugs which possess dose dependent adverse effects like muscle pain, neuropathy, hepatic dysfunction and rhabdomyolysis. Reducing the statin dose, adding drug like proproteinconvertasesubtilisin/kexin type 9 inhibitors, supplements with coenzyme Q10 and L-carnitinie are some of the approaches to reduce statin advderse effects. In future for those patients who cannot tolerate statin and for those who can’t achieve LDL target, squalene synthase inhibitors are the best choice. We focused on current existing hypolipidemic drugs, their targets and mechanism of actions and also the new ideal antilipidemic drugs of future. Ideal antilipidemic drug is one which should produce target lipid level, cause fewer side effects and drug interactions.

Metrics

Metrics Loading ...

References

Kennedy. C, Koller Y, Surkova E. (2020). Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis. Atherosclerosis. 299, 1-8.

Yao, Y.S., Li, T.D. & Zeng, Z.H. (2020). Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids in Health and Disease, 19(23).

Sando KR and Knight M. (2015). Non-statin therapies for management of dyslipidemia: a review. Clinical Therapeutics, 37(10), 2153-2179.

RS Satoskar, Nirmala NR, Raakhi KT and SD Bhandarkar.(2017). Pharmacology and pharmacotherapeutics, 25th Ed. popular prakashan publication, 590-8.

Nelson RH. (2013). Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care, 40(1), 195-211.

Jiang, S., Li, H., Tang, J. et al. (2018). Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nature Communications, 9, 5138.

Toth PP, Banach M. (2019). Statins: Then and now. Methodist Debakey Cardiovascular Journal, 15(1), 23-31.

Golomb BA, Evans MA. (2008). Statin adverse effects: A review of the literature and evidence for a smitochondrial mechanism. American Journal of Cardiovascular Drugs, 8(6), 373-418.

Thangamani S, Mohammad H, Abushakba MF, Hamed MI, Sobreira TJ, Hedrick VE, Paul LN, Seleem MN. (2015). Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Scientific Reports, 5, 16407.

Connie BN, David P, Jonathan AT, Terry AJ, Robert L, Larry BG et al. (2019). Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arteriosclerosis Thrombosis and Vascular Biology, 39, e38-e81.

Spence JD and Dresser GK. (2016). Overcoming challenges with statin therapy. Journal of the American Heart Association, 5(1).

Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ and Kim EM et al. (2019). 2018 Guidelines for the management of dyslipidemia in korea. The Korean Journal of Internal Medicine, 34(5), 1171.

N Stone. (2002). Combination therapy: its rationale and the role of ezetimibe. European Heart Journal supplements, 4, J19-J22.

Al-Shaer, M.H., Choueiri, N.E. & Suleiman, E.S. (2004). The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids in Health and Disease, 3, 22.

E. Leitersdorf. (2001). Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. European Heart Journal Supplements. 3 suppl_ E, E17-E23.

Brown WV. (2003). Cholesterol absorption inhibitors: defining new options in lipid management. Clinical Cardiology, 26, 259-264.

Toma A. (2013). Recent advances on novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonists. International Journal of Pharmaceutical Sciences and Research, 4(5), 1644-1653.

Fagerberg B, Edwards S, Halmos T, et al. (2005). Tesaglitazar, novel dual peroxisome proliferator-activated receptor alpha/gamma agonists, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population, Diabetologia, 48(9), 1716-1725.

Barter PJ, Rye KA. (2016). New era of lipid-lowering drugs, Pharmacological Reviews, 68(2), 458-475.

Nelson RH. (2013). Hyperlipidemia as a risk factor for cardiovascular disease, Prime Care, 40(1), 195-211.

Ann CS, Peter WFW, William SH, Eliot AB, Penny MK and Chesney KR et al. (2019). Omega-3 fatty acids for the management of hypertriglyceridemia: A science advisory from the American Heart Association. Circulation, 140(12), e673-e691.

Raal FJ, Marais AD, Klepack E, Lovalvo J, Mclain R, Heinonen T. (2003). Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis, 171(2), 273-279.

Rudling, M., Camilleri, M., Graffner, H. et al. (2015). Specific inhibitions of bile acid transport alter plasma lipids and GLP-1. BMC Cardiovascular Disorders, 15(75).

Kumagai Y, Amano H, Sasaki Y, Nakagawa C, Maeda M, Oikawa I, Furuie H. (2018). Effect of single and multiple doses of elobixibat, an ileal bile acid transport inhibitor, on chronic constipation: A randomized controlled trial. British Journal of Clinical Pharmacology, 84(10), 2393-2404.

Walter Masson, Lobo Martin Lobo, Daniel Siniawski, Melina Huerin, Graciela Molinero, et al. (2018). Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes and Metabolism, 44(6), 508-513.

Mohammadpour AH and Akhlaghi F. (2013). Future of cholesterol ester transfer (CETP) inhibitors: a pharmacological perspective. Clinical Pharmacokinetics, 52(8), 615-626.

Manocha A and Srivastava LM. (2016). Lipoprotein (a): a unique independent risk factor for coronary artery disease. Indian Journal of Clinical Biochemistry, 31(1), 13-20.

Tsimikas S. (2016). Lp(a) as a new target for reduction of risk of cardiovascular disease and emergence of novel therapies to lower Lp(a). Current Opinion in Endocrinology Diabetes and Obesity, 23(2), 157-164.

Kramer W. (2016). Antilipidemic drug therapy today and in the future. Handbook of Experimental Pharmacology, 233, 373-435.

Hegele RA and Tsimikas S. (2019). Lipid- lowering agents. 124(3), 386-404.

Zodda D, Giammona R and Schifilliti S. (2018). Treatment strategy for dyslipidemia in cardiovascular disease prevention: Focus on old and new drugs. Pharmacy (Basel), 6(1), 10.

Chaudhary R, Garg J, Shah N and Sumner A. (2017). PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology, 9(2), 76-91.

Claudia Stefanutti. (2014). Targeting MTP for the treatment of homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 9(3), 369-381.

Davis KA and Miyares MA. (2014). Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. American Journal of Health-System Pharmacy, 71(12), 1001-1008.

Pinkosky. SL, Filippov S, Srivastava RA, et al. (2013). AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. Journal of Lipid Research, 54(1), 134-151.

Bilen O and Ballantyne CM. (2016). Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Current Atherosclerosis Reports, 18(10), 61.

Bell DA, Hooper AJ and Burnett JR. (2011). Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opinion on Investigational Drug, 20(2), 265-272.

Charlton-Menys V, Durrington PN. (2007). Squalene synthase inhibitors: clinical pharmacology and cholesterol- lowering potential. Drugs, 67(1), 11-16

Reshma GB, Nadar MSAM, Selvakumar PM. (2018). A review on anticholesterol drugs and their mechanisms. Journal of Medicinal Chemistry and Drug Design, 1(1).

Shattat G.F. (2014). A review article on hyperlipidemia: Types, treatments and new drug targets.Biomedical and Pharmacology Journal, 7(2).

Abd-Alkareem HF, Jaber AH, Ibrahim AQ and Fanok MA. (2020). Lipid lessening drugs overview. GSC Biological and Pharmaceutical Sciences, 10(01), 90-95.